Trevi Therapeutics Stock Price, News & Analysis

Trevi Therapeutics announced the pricing of its underwritten public offering of common stock and pre-funded warrants, aiming to raise approximately $50 million. The offering is led by SVB Securities, Stifel, and Oppenheimer & Co. and expected to close on September [__], 2022, pending customary conditions. The shares are sold under a shelf registration statement filed with the SEC. Trevi’s investigational therapy, Haduvio, addresses chronic cough in idiopathic pulmonary fibrosis and prurigo nodularis, with the offering intended to bolster its clinical development efforts.

Trevi Therapeutics has announced a public offering of its common stock and pre-funded warrants to purchase common stock. The offering, managed by SVB Securities, Stifel, and Oppenheimer & Co., is subject to market conditions, with a 30-day option for underwriters to purchase additional shares. The offering is made under a shelf registration statement filed with the SEC, and preliminary terms will be detailed in a forthcoming prospectus supplement. Trevi focuses on developing Haduvio, an investigational therapy for chronic cough and prurigo nodularis.

Trevi Therapeutics (Nasdaq: TRVI) announced positive results from its Phase 2 CANAL trial of Haduvio, an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis. The trial showed a significant reduction in daytime cough frequency, with a 75.1% decrease compared to 22.6% for placebo (p<0.0001). Secondary endpoints also demonstrated consistent efficacy across patient-reported outcomes. The results were consistent with the interim analysis, and the company plans to initiate the next clinical trial in early 2023, as there are no approved therapies for chronic cough in IPF patients.

Trevi Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Jennifer Good, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 10:30 AM ET. The presentation will highlight the investigational therapy Haduvio™ (oral nalbuphine ER), aimed at treating prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis. Trevi is focused on the development of Haduvio, which has received Fast Track designation from the FDA.

Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced a virtual R&D Day scheduled for September 19, 2022, from 10 AM to 12:30 PM ET. The event will feature expert presentations from Dr. Peter Dicpinigaitis and Dr. Brian Kim, focusing on chronic cough and prurigo nodularis. Trevi will provide updates on its investigational therapy Haduvio (oral nalbuphine ER), which aims to address unmet needs in these conditions. Participants can register and access a live webcast of the event.

Trevi Therapeutics, Inc. (TRVI) announced that two late-breaking abstracts have been accepted for oral presentations at upcoming medical conferences. The European Respiratory Society International Congress 2022, held in Barcelona from September 4-6, will feature data from the Phase 2 CANAL trial on the use of Haduvio™ (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF). Similarly, the EADV Congress in Milan from September 7-10 will present findings from the Phase 2b/3 PRISM trial on prurigo nodularis. Both trials reported statistically significant efficacy results.

Trevi Therapeutics reported positive results from the Phase 2b/3 PRISM trial of its investigational therapy, Haduvio™, for treating Prurigo Nodularis. The trial achieved its primary endpoint, with 25% of Haduvio patients showing a significant reduction in itch compared to 14% on placebo (p=0.0157). The company completed a $55 million private placement to support further clinical development. For Q2 2022, Trevi's total cash was $78.9 million, with a net loss of $8.1 million, improved from $9.8 million in Q2 2021.

Future data from the Phase 2 CANAL trial on chronic cough is expected later this quarter.

Trevi Therapeutics, Inc. (NASDAQ: TRVI) announced its participation in two key conferences in August 2022. On August 16, CEO Jennifer Good will engage in a fireside chat at the Stifel Biotech Executive Summer Summit. On August 29, CMO Thomas Sciascia and Professor Toby Maher will co-host a workshop at the 6th Annual IPF Summit in Boston, emphasizing chronic cough treatment strategies. Trevi's investigational therapy Haduvio is being developed for prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis, with FDA Fast Track designation for itch treatment.